中国肿瘤外科杂志2024，Vol.16Issue(2)：105-109,5.DOI:10.3969/j.issn.1674-4136.2024.02.001
中国自主研发的抗乳腺癌新药临床研究进展
Progress of clinical research on new anti-breast cancer drugs independently developed in China
摘要
Abstract
Systemic therapy is one of the important means for breast cancer treatment. In recent years,China has made great progress in the research and development on new anti-breast cancer drugs,which include anti-HER2 therapy,chemotherapy,endocrine therapy and immunotherapy drugs that covers various molecular subtypes of breast cancer,and many of these clinical studies have changed the clinical practice of breast cancer treatment.Therefore,this article summarizes the clinical researches on new anti-breast cancer drugs independently developed in China in recent years,aiming to provide insights for clinical application and future research.关键词
乳腺肿瘤/中国研发药物/临床研究/靶向治疗/内分泌治疗Key words
Breast carcinoma/Chinese-developed drugs/Clinical research/Targeted therapy/Endocrine therapy引用本文复制引用
张朦琦,徐兵河..中国自主研发的抗乳腺癌新药临床研究进展[J].中国肿瘤外科杂志,2024,16(2):105-109,5.基金项目
中国医学科学院医学与健康科技创新工程项目(CIFMS)2021-I2M-1-014 （CIFMS）
